Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.

Weiss GA, Rossi MR, Khushalani NI, Lo K, Gibbs JF, Bharthuar A, Cowell JK, Iyer R.

J Gastrointest Oncol. 2013 Mar;4(1):20-9. doi: 10.3978/j.issn.2078-6891.2012.012.

3.

Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer.

Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Buchsbaum DJ, Vickers SM, Heslin MJ, Arnoletti JP.

Surgery. 2007 Apr;141(4):464-9. Epub 2007 Jan 22.

PMID:
17383523
4.

Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.

Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina PP, Conde E, Tang M, Soler G, Lopez-Encuentra A, Cigudosa JC, Sanchez-Cespedes M.

J Pathol. 2008 Feb;214(3):347-56.

PMID:
17992665
5.

Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.

Brachtel EF, Iafrate AJ, Mark EJ, Deshpande V.

Diagn Cytopathol. 2007 May;35(5):257-62.

PMID:
17427221
6.

PIK3CA mutation status in Japanese lung cancer patients.

Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y.

Lung Cancer. 2006 Nov;54(2):209-15. Epub 2006 Aug 22.

PMID:
16930767
7.

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.

Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM.

Clin Cancer Res. 2005 May 15;11(10):3750-7.

8.

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.

Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K, Park JO.

Cancer. 2007 Apr 15;109(8):1561-9.

9.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

10.

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T.

Cancer Res. 2004 Dec 15;64(24):8919-23.

11.

Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.

Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N.

Int J Oncol. 2008 Jan;32(1):101-11.

PMID:
18097548
12.
13.

Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.

Ren GJ, Zhao YY, Zhu YJ, Xiao Y, Xu JS, Shan B, Zhang L.

Chin Med J (Engl). 2011 Jan;124(1):19-25.

PMID:
21362302
14.

[The relationship between EGFR mutations and response and prognosis of tyrosine kinase inhibitors in advanced Non-small-cell Lung Cancer.].

Zhang X, Xu L, Wang H, Zhu Y, Liu Z, Yue W, Tang J, Wu W, Liu Z, Wu Y, Zhang C, Shi Y, Wang M, Shi H, Li M, Meng Q, Guo L, Wang J, Li X.

Zhongguo Fei Ai Za Zhi. 2008 Apr 20;11(2):206-13. doi: 10.3779/j.issn.1009-3419.2008.02.016. Chinese.

15.

Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.

Riener MO, Bawohl M, Clavien PA, Jochum W.

Genes Chromosomes Cancer. 2008 May;47(5):363-7. doi: 10.1002/gcc.20540.

PMID:
18181165
17.

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F.

J Clin Oncol. 2005 Feb 1;23(4):857-65.

PMID:
15681531
18.

Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung.

Haneda H, Sasaki H, Shimizu S, Endo K, Suzuki E, Yukiue H, Kobayashi Y, Yano M, Fujii Y.

Lung Cancer. 2006 Apr;52(1):47-52. Epub 2006 Feb 28.

PMID:
16503085
19.

Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.

Hayes MP, Douglas W, Ellenson LH.

Gynecol Oncol. 2009 Jun;113(3):370-3. doi: 10.1016/j.ygyno.2008.12.021. Epub 2009 Mar 9.

20.

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas.

Bujko M, Kober P, Tysarowski A, Matyja E, Mandat T, Bonicki W, Siedlecki JA.

Oncol Lett. 2014 Jun;7(6):2019-2022. Epub 2014 Apr 7.

Supplemental Content

Support Center